Skip to main content
SpringerLink
Log in

Antagonizing the cannabinoid receptor Type 1: A dual way to fight obesity

  • Opinion
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hill JO, Wyatt HR, Reed GW, Peters JC. Obesity and the environment: where do we go from here? Science 2003, 299: 853–5.

    Article  CAS  PubMed  Google Scholar 

  2. Marx J. Cellular warriors at the battle of the bulge. Science 2003, 299: 846–9.

    Article  CAS  PubMed  Google Scholar 

  3. Gura T. Obesity drug pipeline not so fat. Science 2003, 299: 849–52.

    Article  CAS  PubMed  Google Scholar 

  4. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54: 161–202.

    Article  CAS  PubMed  Google Scholar 

  5. Kirkham TC, Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 2001, 14: 65–86.

    Article  CAS  PubMed  Google Scholar 

  6. Cota D, Marsicano G, Lutz B, et al. The endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 2003, 27: 289–301.

    Article  CAS  PubMed  Google Scholar 

  7. Werner NA, Koch JE. Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 2003, 967: 290–2.

    Article  CAS  PubMed  Google Scholar 

  8. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410: 822–5.

    Article  PubMed  Google Scholar 

  9. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136: 550–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002, 952: 232–8.

    Article  CAS  PubMed  Google Scholar 

  11. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112: 423–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002, 22: 9612–7.

    CAS  PubMed  Google Scholar 

  13. Ravinet TC, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284: R345–53.

    Google Scholar 

  14. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003, 462: 125–32.

    Article  CAS  PubMed  Google Scholar 

  15. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144: 2195–200.

    Article  CAS  PubMed  Google Scholar 

  16. Liu J, Li H, Burstein SH, Zurier RB, Chen JD. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 2003, 63: 983–92.

    Article  CAS  PubMed  Google Scholar 

  17. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63: 908–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrinology Group, Max-Planck-Institute of Psychiatry, Munich, Germany

    D. Cota

  2. Endocrinology Unit, Department of Internal Medicine and Gastroenterology, Center for Applied Biomedical Research (C.R.B.A.), S.Orsola-Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy

    S. Genghini, R. Pasquali & U. Pagotto MD

Authors
  1. D. Cota
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Genghini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Pasquali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Pagotto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Pagotto MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cota, D., Genghini, S., Pasquali, R. et al. Antagonizing the cannabinoid receptor Type 1: A dual way to fight obesity. J Endocrinol Invest 26, 1041–1044 (2003). https://doi.org/10.1007/BF03348205

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348205

Key-words

Search

Navigation